Back to 
Citadel Advisors LLC
Citadel Advisors LLC
SXTC
Showing 0 of 6 quarters
Position history for Citadel Advisors LLC's holdings in China SXT Pharmaceuticals, Inc.
No. Citadel Advisors exited its SXTC (China SXT Pharmaceuticals) position in Q2 2022. Its Q1 2022 13F listed 266,279 shares worth $75,000. Citadel Advisors first reported SXTC in Q1 2021 and held it in 4 quarterly 13F filings.
Current Value
—
Current Shares
—
Total Value Change
$0
Total Shares Change
0
No position history available for this security.